Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESKIMO: Safety of Eribulin in Advanced Breast Cancer
NCT01961544Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eribulin in breast cancer, sponsored by Eisai Co., Ltd. Primary endpoint: Treatment-emergent Adverse Event and Serious Adverse Event at 3.76 months. Started Jun 2013; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01961544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961544.